Reported 2 days ago
Prime Medicine Inc. is restructuring its operations to concentrate on in vivo programs for genetic liver diseases, including Wilson’s Disease and Alpha-1 Antitrypsin Deficiency, after reporting positive results from its clinical trial for PM359 in Chronic Granulomatous Disease. The company plans to file investigational drug applications for its liver disease programs by 2026, while seeking external options for further development of PM359.
Source: YAHOO